Patiromer - Relypsa
Alternative Names: ILY-105; Patiromer acetate; Patiromer calcium; Patiromer sorbitex calcium; RLY-105; RLY-5016; RLY-5016S; Veltassa; ZG 801Latest Information Update: 18 Mar 2024
At a glance
- Originator Relypsa
- Developer Otsuka Pharmaceutical; Relypsa; Vifor Fresenius Medical Care Renal Pharma; Zeria
- Class Polymers
- Mechanism of Action Potassium binding modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hyperkalaemia
Most Recent Events
- 06 Mar 2024 Phase-II clinical trials in Hyperkalaemia (In neonates, In infants, In children) in USA (PO) (NCT05766839) (EudraCT2023-505252-21-00) (EudraCT2022-501829-20)
- 16 Mar 2023 Vifor Pharma plans the phase II EMERALD-2 trial for Hyperkalemia (In children, In infants, In neonates) in USA (PO) (NCT05766839) (EudraCT2022-501829-20)
- 13 Mar 2023 Zeria Pharmaceutical completes a phase III trial for Hyperkalaemia (In adults, In the elderly) in Japan (PO, Powder) (NCT04955678)